UNC Rex Hospital is a general hospital located in Raleigh, North Carolina. It is the capital city's oldest hospital, founded by a bequest from John T. Rex, a local tanner.

There are 665 beds in UNC REX Healthcare.

During the past decade, UNC REX Healthcare conducted 38 clinical trials. In the 10-year time frame, 38 clinical trials started and 35 clinical trials were completed, i.e. on average, 92.1% percent of trials that started reached the finish line to date. In the past 5 years, 7 clinical trials started and 21 clinical trials were completed. i.e. 300% of trials that started reached the finish line.

Out of the total clinical trials conducted in "UNC REX Healthcare" #1 sponsor was "National Cancer Institute (NCI)" with 16 trials, followed by "Boston Scientific Corporation" with 9 trials sponsored, "UNC Lineberger Comprehensive Cancer Center" with 8 trials sponsored, "C. R. Bard" with 3 trials sponsored and "Mercator MedSystems, Inc." with 3 trials sponsored. Other sponsors include 32 different institutions and companies that sponsored additional 34 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "UNC REX Healthcare" #1 collaborator was "National Cancer Institute (NCI)" with 6 trials as a collaborator, "NRG Oncology" with 5 trials as a collaborator, "North Central Cancer Treatment Group" with 4 trials as a collaborator, "Cancer and Leukemia Group B" with 3 trials as a collaborator and "Canadian Cancer Trials Group" with 2 trials as a collaborator. Other collaborators include 22 different institutions and companies that were collaborators in the rest 29 trials.

According to Clinical.Site data, the most researched conditions in "UNC REX Healthcare" are "Peripheral Arterial Disease" (8 trials), "Coronary Artery Disease" (4 trials), "Peripheral Artery Disease" (4 trials), "Stage IIA Breast Cancer AJCC v6 and v7" (4 trials) and "Stage IIB Breast Cancer AJCC v6 and v7" (4 trials). Many other conditions were trialed in "UNC REX Healthcare" in a lesser frequency.

Most popular intervention types in "UNC REX Healthcare" are "Device" (33 trials), "Drug" (31 trials), "Other" (17 trials), "Biological" (14 trials) and "Procedure" (14 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (13 trials), "Quality-of-Life Assessment" (8 trials), "Paclitaxel" (7 trials), "Bevacizumab" (5 trials) and "Trastuzumab" (5 trials). Other intervention names were less common.

The vast majority of trials in "UNC REX Healthcare" are 68 trials for "All" genders, 7 trials for "Female" genders and 1 trials for "Male" genders.

Currently, there are NaN active trials in "UNC REX Healthcare". undefined are not yet recruiting, 6 are recruiting, 27 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 38 completed trials in UNC REX Healthcare, undefined suspended trials, and 3 terminated clinical trials to date.

Out of the total trials that were conducted in UNC REX Healthcare, 0 "Phase 1" clinical trials were conducted, 14 "Phase 2" clinical trials and 25 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 27 trials that are defined as “Not Applicable".

UNC REX Healthcare has several departments that took part in Clinical trials: "NC Heart and Vascular Research" - 69 trials, "Rex Cancer Center" - 54 trials, "Rex Cancer Center of Wakefield" - 33 trials, "Raleigh Hematology Oncology Associates" - 26 trials, "Rex Hematology Oncology Associates-Cary" - 19 trials, "Rex Hematology Oncology Associates-Blue Ridge" - 13 trials, "Rex Hematology Oncology Associates-Garner" - 10 trials, "NC Heart and Vascular" - 2 trials